Tranexamic acid is widely recommended to reduce blood loss in major joint arthroplasty, but optimal dosing remains unclear—especially in patients with chronic kidney disease. A new personalized dosing regimen, developed by Qi Yang, PhD, uses pharmacokinetic modeling to tailor treatment based on weight and kidney function.

Malignant hyperthermia (MH) is a rare but potentially fatal complication triggered by inhalational anesthetics and succinylcholine in genetically susceptible ICU patients. This expert-led review by Sheila Riazi, Teeda Pinyavat, and Jia Wen Deng provides essential guidance on recognizing and managing MH in critical care. Learn how to identify symptoms early and implement life-saving treatment protocols in the ICU.

Tranexamic acid (TXA) is a common antifibrinolytic agent used to minimize bleeding in cardiac surgery. Up to 50% cardiac surgical patients have chronic renal dysfunction (CRD). Optimal dosing of TXA in CRD remains poorly investigated. This is important as TXA is renally eliminated with accumulation in CRD. High TXA doses are associated with postoperative seizures. This study measures plasma TXA concentrations in CRD cardiac surgical patients for pharmacokinetic modeling and dose adjustment recommendations.